CADRENAL THERAPEUTICS INC (CVKD) Stock Price, Quote, News and Overview
NASDAQ:CVKD - Nasdaq - US1276362076 - Common Stock - Currency: USD
CVKD Quote, Performance and Key Statistics
13.69
+0.15 (+1.11%)
The current stock price of CVKD is 13.69 USD. In the past month the price decreased by -16.22%. In the past year, price increased by 93.94%.
CVKD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 54.56 | 711.54B | ||
| JNJ | JOHNSON & JOHNSON | 15.37 | 371.55B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.7 | 315.08B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.95 | 228.99B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.32 | 222.67B | ||
| MRK | MERCK & CO. INC. | 9.9 | 193.70B | ||
| PFE | PFIZER INC | 7.27 | 132.75B | ||
| SNY | SANOFI-ADR | 11.05 | 119.71B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.55 | 97.87B | ||
| GSK | GSK PLC-SPON ADR | 9.09 | 82.08B | ||
| ZTS | ZOETIS INC | 28.29 | 75.82B | ||
| HLN | HALEON PLC-ADR | 22.55 | 49.75B |
Related stock screener links
About CVKD
Company Profile
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. The company is headquartered in Ponte Vedra, Florida and currently employs 4 full-time employees. The company went IPO on 2023-01-20. The firm is developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions. Tecarfarin has orphan drug and fast track designations from the United States Food and Drug Administration for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib). The company is also pursuing additional regulatory strategies for unmet needs in anticoagulation therapy for patients with left ventricular assist devices (LVADs) and those with thrombotic antiphospholipid syndrome (APS). Tecarfarin is specifically designed to leverage a different metabolism pathway than the commonly prescribed Vitamin K Antagonist (warfarin).
Company Info
CADRENAL THERAPEUTICS INC
822 A1a North, Suite 306
Ponte Vedra FLORIDA US
Employees: 4
Phone: 19043000701
CADRENAL THERAPEUTICS INC / CVKD FAQ
What is the stock price of CADRENAL THERAPEUTICS INC today?
The current stock price of CVKD is 13.69 USD. The price increased by 1.11% in the last trading session.
What is the ticker symbol for CADRENAL THERAPEUTICS INC stock?
The exchange symbol of CADRENAL THERAPEUTICS INC is CVKD and it is listed on the Nasdaq exchange.
On which exchange is CVKD stock listed?
CVKD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CADRENAL THERAPEUTICS INC stock?
8 analysts have analysed CVKD and the average price target is 36.38 USD. This implies a price increase of 165.74% is expected in the next year compared to the current price of 13.69. Check the CADRENAL THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CADRENAL THERAPEUTICS INC worth?
CADRENAL THERAPEUTICS INC (CVKD) has a market capitalization of 26.97M USD. This makes CVKD a Nano Cap stock.
How many employees does CADRENAL THERAPEUTICS INC have?
CADRENAL THERAPEUTICS INC (CVKD) currently has 4 employees.
What are the support and resistance levels for CADRENAL THERAPEUTICS INC (CVKD) stock?
CADRENAL THERAPEUTICS INC (CVKD) has a support level at 13.32 and a resistance level at 15.2. Check the full technical report for a detailed analysis of CVKD support and resistance levels.
Should I buy CADRENAL THERAPEUTICS INC (CVKD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CVKD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CVKD, evaluating the profitability, health, valuation and growth aspects
- CADRENAL THERAPEUTICS INC (CVKD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CADRENAL THERAPEUTICS INC (CVKD) Sales and EPS estimates to see what analysts future expectations are.
- CADRENAL THERAPEUTICS INC (CVKD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CADRENAL THERAPEUTICS INC (CVKD) Insider and Institutional Ownership to learn about the owners and their transactions.
- CADRENAL THERAPEUTICS INC (CVKD) Stock Chart to make your own analysis
- CADRENAL THERAPEUTICS INC (CVKD) Latest news and press-releases to stay up to date.
Does CADRENAL THERAPEUTICS INC (CVKD) stock pay dividends?
CVKD does not pay a dividend.
When does CADRENAL THERAPEUTICS INC (CVKD) report earnings?
CADRENAL THERAPEUTICS INC (CVKD) will report earnings on 2025-08-07.
What is the Price/Earnings (PE) ratio of CADRENAL THERAPEUTICS INC (CVKD)?
CADRENAL THERAPEUTICS INC (CVKD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.26).
What is the Short Interest ratio of CADRENAL THERAPEUTICS INC (CVKD) stock?
The outstanding short interest for CADRENAL THERAPEUTICS INC (CVKD) is 3.7% of its float. Check the ownership tab for more information on the CVKD short interest.
CVKD Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CVKD. When comparing the yearly performance of all stocks, CVKD is one of the better performing stocks in the market, outperforming 92.67% of all stocks.
CVKD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CVKD. While CVKD has a great health rating, there are worries on its profitability.
CVKD Financial Highlights
Over the last trailing twelve months CVKD reported a non-GAAP Earnings per Share(EPS) of -9.26. The EPS increased by 5.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -161.36% | ||
| ROE | -209.93% | ||
| Debt/Equity | 0 |
CVKD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CVKD. The Buy consensus is the average rating of analysts ratings from 8 analysts.